



## PRESS RELEASE

# Alpha IVF Group PATMI of RM25.3 million in 1H24 driven by rising demand for IVF

- *Fertility care specialist benefits from medical tourism and growing domestic demand*
- *Sets to list on the ACE Market of Bursa Malaysia Securities Berhad on 22 March 2024*

KUALA LUMPUR, Malaysia, 19 March 2024 - Fertility care specialist, Alpha IVF Group Berhad (“Alpha IVF Group”; Bursa Ticker: 0303) and its subsidiaries (collectively referred to as “the Group” or “阿儿法国际辅助生殖集团”) posted a net profit attributable to shareholders (PATMI) of RM25.3 million on group revenue of RM80.1 million for the six months ended 30 November 2023 (1H24).

As the Group is not yet a publicly-listed entity, there are no comparative figures for the same period in previous year.

In the previous financial year ended 31 May 2023 (FYE 2023), the Group recorded RM137.5 million revenue and RM53.2 million PATMI. The PATMI in FYE 2023 included a fair value gain of RM11.3 million, without which the Group’s core PATMI would have been RM41.9 million.

On annualized basis, the better performance in 1H24 compared to that of FYE 2023 was attributable to a rise in demand for In-vitro Fertilisation (IVF) treatments, which was driven not just by medical tourism as borders reopened, mainly from Indonesian and Chinese patients, but also by increasing domestic demand.

**Dato’ Dr Colin Lee Soon Soo (拿督 李顺树医生), Group Managing Director of Alpha IVF Group Berhad said:**

“Our 2Q24 financial performance highlights Alpha IVF Group’s ability to ride the wave of medical tourism and the growing need for IVF treatments. Our positive financial performance, along with our imminent listing and enhanced profile in the public eye, allows us to capitalise on new market opportunities.

We will continue to put our growth plans in motion, including expanding our business locally and regionally and simultaneously addressing the burgeoning demand.”

In the second quarter ended 30 November 2023 (2Q24), Alpha IVF Group registered revenue of RM38.5 million and PATMI of RM12.2 million.

Alpha IVF Group is scheduled to be listed on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Malaysia) on 22 March 2024, at an issue price of 0.32 sen per share. Alpha IVF Group’s market capitalisation would be RM1.6 billion, making it the largest ACE Market initial public offering on Bursa Malaysia.



From the total proceeds raised of RM116.6 million, RM72.8 million will be utilised to develop new IVF centres, satellite clinics, and sales representative offices as part of their domestic and global expansion strategy.

A further RM15.7 million will be allocated for expansion and upgrade of existing specialist centres, facilities, and corporate office; RM2.2 million for research and development (R&D), as well as the remaining RM25.9 million for general working capital, general corporate purposes, and defraying of listing expenses.

Alpha IVF Group has a committed dividend policy and aims to distribute at least 60% of the annual audited profit after tax attributable to shareholders to reward the shareholders.

---

## **About Alpha IVF Group Berhad (“Alpha IVF Group”)**

Alpha IVF Group is one of the largest fertility care specialists, currently operating in Malaysia and Singapore. The group primarily focuses on Assisted Reproductive Services (ARS), with a strong emphasis on In-vitro Fertilisation (IVF). Presently, the group operates two specialist centres in Malaysia - Alpha International Women’s Specialists Sdn Bhd (“Alpha KL”) in Kuala Lumpur and Genesis Specialists Sdn Bhd (“Genesis”) in Penang - and one in Singapore known as Alpha International Women’s Specialists (Singapore) Pte Ltd (“Alpha Singapore”).

In addition to IVF, Alpha IVF Group provides various assisted reproductive procedures, including intracytoplasmic sperm injection, intrauterine insemination, diagnostics, testing, screening procedures, and cryopreservation of eggs, sperms, and embryos.

Since its inception in 2011, Alpha IVF Group has earned a strong reputation, with its brand synonymous with exceptional success rates in IVF. The high pregnancy rates are attributed to the group’s robust foundation, known as the “system of systems,” and its five strategic pillars: leading medical specialists, highly skilled embryologists, continuous research and development, innovative techniques, and cutting-edge laboratory equipment.

Alpha IVF Group’s operations have provided IVF services to international patients from Indonesia, China, Singapore, Australia, and other countries. The group has also pioneered numerous innovations leading to improved pregnancy rates and is actively involved in utilizing Artificial Intelligence technology to enhance embryo selection for higher IVF success rates.

**Issued for and on behalf of ALPHA IVF GROUP BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.  
For media enquiries, please contact:**

Ms. Azja Delana

[azja@aquilas.com.my](mailto:azja@aquilas.com.my)

T: 03-2711 1391 / 019-5886 088